Treated secondary acute myeloid leukemia: A distinct high-risk subset of AML with adverse prognosis

Prajwal Boddu, Hagop M. Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi, Srdan Verstovsek, Elias Jabbour, Gautam Borthakur, Marina Konopleva, Kapil N. Bhalla, Naval Daver, Courtney D. DiNardo, Christopher B. Benton, Koichi Takahashi, Zeev Estrov, Sherry R. Pierce, Michael Andreeff, Jorge E. Cortes, Tapan M. Kadia

Research output: Contribution to journalArticle

Abstract

Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and (2) at least 1 therapy for that diagnosis. ts-AML was categorized by age (, or $60 years), and each cohort assessed for response rates and overall survival (OS) on various treatment regimens. Survival outcomes were compared against other high-risk prognostic subsets. Results showed that complete response and 8-week mortality rates were 32% and 27% in the younger, and 24% and 19% in the older age groups, respectively. There was a significant OS difference within s-AML based on prior treatment of AHD (ie, ts-AML vs s-AML with untreated AHD, 4.2 vs 9.2 months; P, .001). Survival in ts-AML was poor across both cohorts (younger and older, 5 and 4.7 months, respectively). In younger AML, survival was significantly inferior in ts-AML when compared with deletion 5/7, TP53, 3q abnormality, and therapy-related AML groups (median, 5 vs 7.9, 7.8, 7.9, and 11.2 months, respectively; P, .01). Additional adverse karyotype within ts-AML was associated with even worse outcomes (OS range, 1.6-2.8 months). ts-AML represents a very high-risk category, even in younger AML patients. s-AML should be further classified to describe ts-AML, an entity less responsive to currently applied treatment approaches. Future AML trial designs should accommodate ts-AML as a distinct subgroup.

Original languageEnglish (US)
Pages (from-to)1312-1323
Number of pages12
JournalBlood Advances
Volume1
Issue number17
DOIs
StatePublished - Jul 25 2017
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Survival
Therapeutics
Aplastic Anemia
Karyotype
Survival Rate
Age Groups
Mortality
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Boddu, P., Kantarjian, H. M., Garcia-Manero, G., Ravandi, F., Verstovsek, S., Jabbour, E., ... Kadia, T. M. (2017). Treated secondary acute myeloid leukemia: A distinct high-risk subset of AML with adverse prognosis. Blood Advances, 1(17), 1312-1323. https://doi.org/10.1182/bloodadvances.2017008227

Treated secondary acute myeloid leukemia : A distinct high-risk subset of AML with adverse prognosis. / Boddu, Prajwal; Kantarjian, Hagop M.; Garcia-Manero, Guillermo; Ravandi, Farhad; Verstovsek, Srdan; Jabbour, Elias; Borthakur, Gautam; Konopleva, Marina; Bhalla, Kapil N.; Daver, Naval; DiNardo, Courtney D.; Benton, Christopher B.; Takahashi, Koichi; Estrov, Zeev; Pierce, Sherry R.; Andreeff, Michael; Cortes, Jorge E.; Kadia, Tapan M.

In: Blood Advances, Vol. 1, No. 17, 25.07.2017, p. 1312-1323.

Research output: Contribution to journalArticle

Boddu, P, Kantarjian, HM, Garcia-Manero, G, Ravandi, F, Verstovsek, S, Jabbour, E, Borthakur, G, Konopleva, M, Bhalla, KN, Daver, N, DiNardo, CD, Benton, CB, Takahashi, K, Estrov, Z, Pierce, SR, Andreeff, M, Cortes, JE & Kadia, TM 2017, 'Treated secondary acute myeloid leukemia: A distinct high-risk subset of AML with adverse prognosis', Blood Advances, vol. 1, no. 17, pp. 1312-1323. https://doi.org/10.1182/bloodadvances.2017008227
Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E et al. Treated secondary acute myeloid leukemia: A distinct high-risk subset of AML with adverse prognosis. Blood Advances. 2017 Jul 25;1(17):1312-1323. https://doi.org/10.1182/bloodadvances.2017008227
Boddu, Prajwal ; Kantarjian, Hagop M. ; Garcia-Manero, Guillermo ; Ravandi, Farhad ; Verstovsek, Srdan ; Jabbour, Elias ; Borthakur, Gautam ; Konopleva, Marina ; Bhalla, Kapil N. ; Daver, Naval ; DiNardo, Courtney D. ; Benton, Christopher B. ; Takahashi, Koichi ; Estrov, Zeev ; Pierce, Sherry R. ; Andreeff, Michael ; Cortes, Jorge E. ; Kadia, Tapan M. / Treated secondary acute myeloid leukemia : A distinct high-risk subset of AML with adverse prognosis. In: Blood Advances. 2017 ; Vol. 1, No. 17. pp. 1312-1323.
@article{9b23739b6e6e4d6f93f8aeb21c08fa20,
title = "Treated secondary acute myeloid leukemia: A distinct high-risk subset of AML with adverse prognosis",
abstract = "Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and (2) at least 1 therapy for that diagnosis. ts-AML was categorized by age (, or $60 years), and each cohort assessed for response rates and overall survival (OS) on various treatment regimens. Survival outcomes were compared against other high-risk prognostic subsets. Results showed that complete response and 8-week mortality rates were 32{\%} and 27{\%} in the younger, and 24{\%} and 19{\%} in the older age groups, respectively. There was a significant OS difference within s-AML based on prior treatment of AHD (ie, ts-AML vs s-AML with untreated AHD, 4.2 vs 9.2 months; P, .001). Survival in ts-AML was poor across both cohorts (younger and older, 5 and 4.7 months, respectively). In younger AML, survival was significantly inferior in ts-AML when compared with deletion 5/7, TP53, 3q abnormality, and therapy-related AML groups (median, 5 vs 7.9, 7.8, 7.9, and 11.2 months, respectively; P, .01). Additional adverse karyotype within ts-AML was associated with even worse outcomes (OS range, 1.6-2.8 months). ts-AML represents a very high-risk category, even in younger AML patients. s-AML should be further classified to describe ts-AML, an entity less responsive to currently applied treatment approaches. Future AML trial designs should accommodate ts-AML as a distinct subgroup.",
author = "Prajwal Boddu and Kantarjian, {Hagop M.} and Guillermo Garcia-Manero and Farhad Ravandi and Srdan Verstovsek and Elias Jabbour and Gautam Borthakur and Marina Konopleva and Bhalla, {Kapil N.} and Naval Daver and DiNardo, {Courtney D.} and Benton, {Christopher B.} and Koichi Takahashi and Zeev Estrov and Pierce, {Sherry R.} and Michael Andreeff and Cortes, {Jorge E.} and Kadia, {Tapan M.}",
year = "2017",
month = "7",
day = "25",
doi = "10.1182/bloodadvances.2017008227",
language = "English (US)",
volume = "1",
pages = "1312--1323",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "17",

}

TY - JOUR

T1 - Treated secondary acute myeloid leukemia

T2 - A distinct high-risk subset of AML with adverse prognosis

AU - Boddu, Prajwal

AU - Kantarjian, Hagop M.

AU - Garcia-Manero, Guillermo

AU - Ravandi, Farhad

AU - Verstovsek, Srdan

AU - Jabbour, Elias

AU - Borthakur, Gautam

AU - Konopleva, Marina

AU - Bhalla, Kapil N.

AU - Daver, Naval

AU - DiNardo, Courtney D.

AU - Benton, Christopher B.

AU - Takahashi, Koichi

AU - Estrov, Zeev

AU - Pierce, Sherry R.

AU - Andreeff, Michael

AU - Cortes, Jorge E.

AU - Kadia, Tapan M.

PY - 2017/7/25

Y1 - 2017/7/25

N2 - Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and (2) at least 1 therapy for that diagnosis. ts-AML was categorized by age (, or $60 years), and each cohort assessed for response rates and overall survival (OS) on various treatment regimens. Survival outcomes were compared against other high-risk prognostic subsets. Results showed that complete response and 8-week mortality rates were 32% and 27% in the younger, and 24% and 19% in the older age groups, respectively. There was a significant OS difference within s-AML based on prior treatment of AHD (ie, ts-AML vs s-AML with untreated AHD, 4.2 vs 9.2 months; P, .001). Survival in ts-AML was poor across both cohorts (younger and older, 5 and 4.7 months, respectively). In younger AML, survival was significantly inferior in ts-AML when compared with deletion 5/7, TP53, 3q abnormality, and therapy-related AML groups (median, 5 vs 7.9, 7.8, 7.9, and 11.2 months, respectively; P, .01). Additional adverse karyotype within ts-AML was associated with even worse outcomes (OS range, 1.6-2.8 months). ts-AML represents a very high-risk category, even in younger AML patients. s-AML should be further classified to describe ts-AML, an entity less responsive to currently applied treatment approaches. Future AML trial designs should accommodate ts-AML as a distinct subgroup.

AB - Secondary acute myeloid leukemia (s-AML) includes therapy-related AML and AML evolving from antecedent hematological disorder (AHD). s-AML arising after treating AHD likely represents a prognostically distinct, high-risk disease category. In this study, treated s-AML (ts-AML) was defined by: (1) prior diagnosis of myelodysplasia, myeloproliferative neoplasm, or aplastic anemia and (2) at least 1 therapy for that diagnosis. ts-AML was categorized by age (, or $60 years), and each cohort assessed for response rates and overall survival (OS) on various treatment regimens. Survival outcomes were compared against other high-risk prognostic subsets. Results showed that complete response and 8-week mortality rates were 32% and 27% in the younger, and 24% and 19% in the older age groups, respectively. There was a significant OS difference within s-AML based on prior treatment of AHD (ie, ts-AML vs s-AML with untreated AHD, 4.2 vs 9.2 months; P, .001). Survival in ts-AML was poor across both cohorts (younger and older, 5 and 4.7 months, respectively). In younger AML, survival was significantly inferior in ts-AML when compared with deletion 5/7, TP53, 3q abnormality, and therapy-related AML groups (median, 5 vs 7.9, 7.8, 7.9, and 11.2 months, respectively; P, .01). Additional adverse karyotype within ts-AML was associated with even worse outcomes (OS range, 1.6-2.8 months). ts-AML represents a very high-risk category, even in younger AML patients. s-AML should be further classified to describe ts-AML, an entity less responsive to currently applied treatment approaches. Future AML trial designs should accommodate ts-AML as a distinct subgroup.

UR - http://www.scopus.com/inward/record.url?scp=85048810404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048810404&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2017008227

DO - 10.1182/bloodadvances.2017008227

M3 - Article

C2 - 29296774

AN - SCOPUS:85048810404

VL - 1

SP - 1312

EP - 1323

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 17

ER -